The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.


Journal Article

Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes.The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A(1)-receptor antagonist, in patients with acute heart failure.The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. Intravenous rolofylline 30 mg or placebo was infused over 4 hours daily for up to 3 days. Adverse events (AEs) and serious AEs (SAEs) were recorded from baseline through 7 and 14 days, respectively, and clinical events were adjudicated through 60 days.Of 2033 patients enrolled, 2002 received study drug randomized 2 : 1 to rolofylline or placebo. Rolofylline and placebo were associated with a similar risk of pre-specified groups of AEs or SAEs, other than selected neurological events. Investigator-reported seizures occurred in 11 (0.8%) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). Stroke occurred in 21 (1.6%) patients assigned to rolofylline compared with 3 (0.5%) placebo-treated patients through 60 days with a greater risk for stroke in the rolofylline group (hazard ratio 3.49; 95% CI 1.04, 11.71; p = 0.043). There was no temporal relation to rolofylline administration and no specific stroke subtype or clinical characteristics that predicted stroke in the rolofylline group.Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A(1)-receptor antagonists. An unanticipated, disproportionate increase in strokes in the rolofylline-treated patients emerged, although no clear temporal relation, aetiology, stroke subtype or interacting factor suggestive of a causal mechanism was identified. Further research into stroke as a potential complication of adenosine-modulating therapies is required. Additionally, this study underscores the value of longer follow-up durations for AEs, even for agents with short treatment periods, such as in acute heart failure.

Full Text

Duke Authors

Cited Authors

  • Teerlink, JR; Iragui, VJ; Mohr, JP; Carson, PE; Hauptman, PJ; Lovett, DH; Miller, AB; Piña, IL; Thomson, S; Varosy, PD; Zile, MR; Cleland, JGF; Givertz, MM; Metra, M; Ponikowski, P; Voors, AA; Davison, BA; Cotter, G; Wolko, D; Delucca, P; Salerno, CM; Mansoor, GA; Dittrich, H; O'Connor, CM; Massie, BM

Published Date

  • March 2012

Published In

Volume / Issue

  • 35 / 3

Start / End Page

  • 233 - 244

PubMed ID

  • 22339573

Pubmed Central ID

  • 22339573

Electronic International Standard Serial Number (EISSN)

  • 1179-1942

International Standard Serial Number (ISSN)

  • 0114-5916

Digital Object Identifier (DOI)

  • 10.2165/11594680-000000000-00000


  • eng